Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Most claims align with FDA label content provided (indication for hypothyroidism, narrow therapeutic index, undertreatment/overtreatment risks, need for careful titration/monitoring, general overdosage symptoms as hyperthyroidism, and missed-dose handling structure). However, several key claims are not supported by the provided label excerpts (tablet scoring/divisibility, acceptability of splitting, individualized dosing based on age/weight/medical history, specific dosing range, and specific empty-stomach/30–60 minute timing).
Category Scores
Accurate Statements
If too little Synthroid is taken, it can lead to symptoms of hypothyroidism (underactive thyroid).
Supported by Section 5.1 describing negative effects of undertreatment; label excerpt does not explicitly list 'symptoms,' but it is consistent with undertreatment risk.
If too much Synthroid is taken, it can lead to symptoms of hyperthyroidism (overactive thyroid).
Supported by Section 5.1 (overtreatment effects) and Section 6/10 indicating adverse reactions and overdosage signs/symptoms are those of hyperthyroidism.
If a dose of Synthroid is missed, it should be taken as soon as remembered unless it is close to the time of the next scheduled dose.
Not supported or contradicted by the provided label excerpts.
If a dose of Synthroid is missed and it is close to the time of the next scheduled dose, the missed dose should be skipped.
Not supported or contradicted by the provided label excerpts.
After missing a dose of Synthroid, a double dose should not be taken to compensate.
Not supported or contradicted by the provided label excerpts.
Unsupported Statements
Synthroid tablets are scored, meaning they have a line imprinted on them to facilitate division.
No provided label excerpt includes tablet scoring or divisibility information.
The scoring on Synthroid tablets is intended to allow patients to split tablets for easier swallowing or to achieve half-dosing if prescribed by a healthcare professional.
No provided label excerpt explains the purpose of scoring or tablet-splitting rationale.
Cutting a scored Synthroid tablet in half is generally acceptable.
No provided label excerpt states that splitting is acceptable or provides related instructions.
A doctor may recommend splitting Synthroid tablets to adjust dosage.
No provided label excerpt states that tablet splitting is part of dosing adjustments.
Synthroid dosage is individualized based on a patient's age, weight, medical history, and thyroid hormone levels.
Section 5.1 supports careful titration/monitoring, but the provided excerpts do not specify factors such as age/weight/medical history.
Synthroid dosages can range from 25 to 300 micrograms daily.
The provided excerpts do not contain a numeric dosing range.
Synthroid is typically taken once daily on an empty stomach.
The provided excerpts do not include administration timing/frequency instructions.
Synthroid is typically taken 30 to 60 minutes before breakfast to ensure optimal absorption.
The provided excerpts do not include a 30–60 minute instruction.
Synthroid is typically taken once daily on an empty stomach.
Not supported by provided label excerpts.
Synthroid dosage is individualized based on a patient's age, weight, medical history, and thyroid hormone levels.
Not supported by provided label excerpts.
Contradictions
Low
AI Statement
Synthroid is typically taken once daily on an empty stomach.
Label Reference
Important Omissions
Missed-dose instructions, if any, including specific guidance on what to do (timing/window, whether to take immediately vs skip) are not verifiable from the provided label excerpts.
Importance:
Moderate
The response does not mention the boxed warning that SYNTHROID should not be used for obesity/weight loss (including patient counseling that it should not be used as primary or adjunctive therapy in a weight control program).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Claims about tablet splitting, empty-stomach/30–60 minute timing, and specific dosing range are not supported by the provided label excerpts; incorrect administration or dosing guidance could affect safety. However, overtreatment/undertreatment risk framing is broadly consistent with provided labeling (Section 5.1 and hyperthyroidism overdosage/adverse reaction content).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several dosing/administration and tablet-splitting details are unsupported by the provided FDA label excerpts.
Suggested Improvement
Limit statements to label-supported content from the provided sections (e.g., narrow therapeutic index; risks of overtreatment/undertreatment; adverse reactions/overdosage signs consistent with hyperthyroidism). Remove or qualify unsupported claims about scoring/tablet splitting, empty-stomach timing, and specific dosing range unless supported by the relevant label sections not included in the prompt.